IGC Pharma, Inc. (IGC)
0.3492
+0.05
(+17.18%)
USD |
NYAM |
Dec 10, 16:00
0.3545
+0.01
(+1.52%)
After-Hours: 19:41
IGC Pharma Cash from Investing (Quarterly): -0.374M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Esperion Therapeutics, Inc. | -- |
| Theravance Biopharma, Inc. | -100.25M |
| NRX Pharmaceuticals, Inc. | -2.561M |
| CEL-SCI Corp. | 0.00 |
| AIM ImmunoTech, Inc. | 0.296M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.09M |
| Cash from Financing (Quarterly) | 3.11M |
| Free Cash Flow | -6.262M |
| Free Cash Flow Per Share (Quarterly) | -0.0267 |
| Free Cash Flow to Equity (Quarterly) | -2.361M |
| Free Cash Flow to Firm (Quarterly) | -2.416M |
| Free Cash Flow Yield | -21.61% |